Hypothalamic nutrient sensing activates a forebrain-hindbrain neuronal circuit to regulate glucose production in vivo

Carol K.L. Lam\textsuperscript{1,2}, Madhu Chari\textsuperscript{1,2}, Guy A. Rutter\textsuperscript{4} & Tony K. T. Lam\textsuperscript{1,2,3}

\textsuperscript{1}Toronto General Research Institute, University Health Network; Toronto, M5G 1L7, Canada
\textsuperscript{2}Department of Physiology and \textsuperscript{3}Department of Medicine, University of Toronto, Toronto, M5S 1A8, Canada.
\textsuperscript{4}Section of Cell Biology, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College, South Kensington, London, SW7 2AZ, UK

Running title: A hypothalamic-DVC axis that regulates glucose production

Address correspondence to:
Tony Lam
Email: tony.lam@uhnres.utoronto.ca

Submitted 18 July 2010 and accepted 14 September 2010.

Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
**Objective** – Hypothalamic nutrient sensing regulates glucose production but the neuronal circuits involved remain largely unknown. Recent studies underscore the importance of N-methyl-D-aspartate (NMDA) receptors in the dorsal vagal complex in glucose regulation. These studies raise the possibility that hypothalamic nutrient sensing activates a forebrain-hindbrain NMDA dependent circuit to regulate glucose production.

**Research design and methods** – We implanted bilateral catheters targeting the mediobasal hypothalamus (MBH; forebrain) and dorsal vagal complex (DVC; hindbrain) and performed i.v. catheterizations to the same rat for infusion and sampling purposes. This model enabled concurrent selective activation of MBH nutrient sensing by either MBH delivery of lactate or an adenovirus expressing the dominant negative form of AMPK (Ad-DN AMPK α2 [D157A]) and inhibition of DVC NMDA receptors by either DVC delivery of NMDA receptor blocker MK-801 or an adenovirus expressing the shRNA of NR1 subunit of NMDA receptors (Ad-shRNA NR1). Tracer-dilution methodology and the pancreatic euglycemic clamp technique were performed to assess changes in glucose kinetics in the same conscious, unrestrained rat *in vivo*.

**Results** – MBH lactate or Ad-DN AMPK with DVC saline increased glucose infusion required to maintain euglycemia due to an inhibition of glucose production during the clamps. However, DVC MK-801 negated the ability of MBH lactate or Ad-DN AMPK to increase glucose infusion and lower glucose production. Molecular knockdown of DVC NR1 of NMDA receptor via Ad-shRNA NR1 injection also negated MBH Ad-DN AMPK to lower glucose production.

**Conclusions** – Molecular and pharmacological inhibition of DVC NMDA receptors negated hypothalamic nutrient sensing mechanisms activated by lactate metabolism or AMPK inhibition to lower glucose production. Thus, DVC NMDA receptor is required for hypothalamic nutrient sensing to lower glucose production and that hypothalamic nutrient sensing activates a forebrain-hindbrain circuit to lower glucose production.

Hypothalamic nutrient and hormonal sensing regulate glucose and lipid homeostasis (1-7). Although much effort has been put in by laboratories to elucidate the neuronal circuits involved in glucose regulation, an experimental challenge remains in assessing whether extra-hypothalamic regions are involved in relaying the hypothalamic signal(s) to the liver to regulate glucose production.

The dorsal vagal complex (DVC) within the hindbrain processes peripheral signals to regulate homeostasis (8-11). N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the DVC is recently shown to be sufficient (12) and necessary for gut nutrient sensing (13;14) to regulate glucose production. Although one study reports that hypothalamic lipid sensing elucidate DVC neuronal activation in association with an inhibition of glucose production (15), the necessity of the DVC neuronal activation and the neuronal population involved in hypothalamic regulation of glucose production remain unknown.

We here attempted to elucidate in conscious, unrestrained rodents whether direct activation of hypothalamic nutrient sensing by either an enhancement of hypothalamic lactate metabolism (16;17) or a molecular knock-down of hypothalamic AMP-activated
protein kinase (AMPK) (18) triggers a forebrain-hindbrain NMDA dependent axis to lower glucose production. To address this, we inhibited NMDA receptor-mediated neuronal transmission in the DVC hindbrain in the same rats whose nutrient sensing in the forebrain hypothalamus was activated, and examined whether glucose regulation was affected accordingly.

**RESEARCH DESIGN AND METHODS**

All study protocols were approved by the Institutional Animal Care and Use Committee of UHN. Eight-week-old male SD rats were used and were housed in individual cages and maintained on a standard light-dark cycle with access to standard rat chow and water ad libitum. Rats were stereotaxically implanted with indwelling bilateral catheters into both the mediobasal hypothalamus (MBH, 3.1 mm posterior of bregma, 0.4 mm lateral from midline, 9.6 mm below skull surface) (19) and dorsal vagal complex (DVC, 0.0 mm on occipital crest, 0.4 mm lateral to midline, 7.9 mm below skull surface) (12). After one week of recovery, rats underwent iv catheterization where the internal jugular vein and carotid artery were catheterized for infusion and sampling. Knowledge Bank

**MBH/DVC infusion and pancreatic-euglycemic clamp.** Four days post-i.v. catheterization, animals whose food intake and body weight had recovered back to within 10% of baseline underwent the clamp studies. Rats were restricted to ~ 55 kcal of food the night before the experiment to ensure the same nutritional status during the clamps, which lasted 210 min. At t = 0min, MBH/DVC infusions were initiated and maintained throughout the clamps at 0.33 µl/hr. The groups were: (A) MBH saline + DVC saline, (B) MBH saline + DVC MK-801 (0.06 ng/min), (C) MBH lactate (5 mM) + DVC saline, and (D) MBH lactate (5 mM) + DVC MK-801 (0.06 ng/min, with 2 hr preinfusion starting at t = -120 min). A primed-continuous infusion of [3-3H] glucose (Perkin Elmer; 40 µCi bolus; 0.4 µCi/min) was initiated at 0 min and maintained throughout. A pancreatic (basal insulin)-euglycemic clamp was started at t = 90 min until 210 min. Somatostatin (3 µg/kg/min) was infused in along with insulin (0.8 mU/kg/min) to replace insulin back to basal (Supplemental Table S1 in the online appendix available at [http://diabetes.diabetesjournals.org](http://diabetes.diabetesjournals.org)). A 25% glucose solution was started and periodically adjusted to maintain plasma glucose levels (Table S1). Samples for the determination of [3-3H] glucose specific activity and insulin levels were obtained at 10-min intervals. At the end, the rats were anesthetized and 3 µl of diluted bromophenol blue (BPB) was injected through each side of the MBH catheter to ensure the correct placement of the catheter upon dissecting a MBH wedge that contains the entire mediolateral and dorsoventral extent of the arcuate nuclei while minimizing ventromedial nucleus tissue. In parallel, the DVC was sampled by injecting 3 µl (volume found to be restricted locally to the DVC) of BPB via the DVC cannulae and cutting coronally across the medulla. Upon verifying that the location of the BPB-staining in the coronal sections was anatomically representative of the DVC, DVC tissues were obtained by dissecting the BPB-stained regions. To a different set of rats, we also performed tracer infusion to verify cannule location. Radioactive glucose tracer [3-3H] was administrated via the bilateral cannulae into the MBH or DVC at the same infusion rate (0.33 µl/hr) and duration (210 min) as the clamps. MBH, DVC and cortical tissue samples were obtained and were homogenized for counting.

**MBH/DVC adenoviral infection and pancreatic-euglycemic clamp.** Immediately post-stereotaxic surgery, rats were injected 3 µl of adenovirus per side of cannulae into the MBH and/or DVC as described (12;18;20). The adenoviral infected-groups were: (A) MBH GFP + DVC saline, (B) MBH GFP + DVC MK-801, (C) MBH DN AMPK + DVC saline, (D) MBH DN AMPK + DVC MK-801, (E) MBH GFP + DVC shRNA NR1, (G) MBH DN AMPK + DVC mismatch control (mm), (H) MBH DN AMPK + DVC shRNA NR1. We previously validated the specificity of brain injections of these adenoviruses (12;18). GFP was localized in the MBH with 40% co-localized with AgRP-positive neurons and another ~ 40% co-localized with POMC-positive neurons in MBH Ad-GFP injected rats (18). Furthermore, MBH Ad-DN AMPK injection decreased hypothalamic AMPK activity by ~ 50% (18). DVC injection of Ad-shRNA NR1 decreased NR1 protein levels in the DVC but not in the MBH wedges (12). This
was confirmed by IHC showing that NR1 expression within the DVC was reduced in rats injected with DVC shRNA-NR1 (12). Four days post-i.v. catheterization, animals with MBH GFP + DVC null and MBH AMPK + DVC null were infused with either DVC saline or MK-801 from t = 0 min to 210 min at 0.33 µl/hr. Initially, MK-801 was given at 0.03 ng/min as it was previously shown that DVC MK-801 negated the gut lipid-sensing mechanism to lower glucose production (13;14). However, when this dose of MK-801 was infused in DN AMPK-infected rats, it only partially blocked the glucose production-lowering effect (GP suppression: -42.5%). Given such, MK-801 dose was doubled (0.06 ng/min in 210 min; 12 ng) and was found to fully abolish the GP-lowering effect of DN AMPK (Fig 2d,e), while no effect on cumulative food intake was detected (Fig 4c). Hence, this dose of DVC MK-801 was used for all studies. 

Fasting-refeeding experiment. Seven days post-stereotaxic surgery (DVC cannulae), animals whose food intake and body weight had recovered back to baseline underwent the fasting-refeeding studies. Rats were fasted for 40 hours. Thirty min before completion of the fast, rats began a DVC infusion of either saline or MK-801 and upon completion of the fast, rats were fed ad libitum on regular chow diet. Blood glucose levels and food intake were measured. 

Biochemical analysis. Plasma glucose concentrations were measured by the glucose oxidase method (Glucose Analyzer GM9, Lunenbertg, MA). Plasma insulin levels were determined by radioimmunoassay (RIA) (Linco Research, St. Charles, MO). 

Statistical analysis. Statistical analysis was done by two-way ANOVA to compare across the groups followed by Tukey post hoc test to compare between groups. Statistical analysis was accepted as significant with a P value of < 0.05. Data are presented as means ± SE.

RESULTS
We first developed a model that received bilateral catheters into both the MBH and DVC (Fig. 1a,b). On day 7, [3-3H] glucose was infused at same rate as hypothalamic lactate or DVC MK-801 either into the MBH or DVC (Fig. 1a,b). MBH [3-3H] glucose selectively increased radioactive counts in the MBH but not in the DVC of the same rats (Fig. 1c). DVC [3-3H] glucose increased radioactive counts in the DVC but not MBH (Fig. 1c). Counts were not detected in cortex samples (Fig. 1c). Thus, a rat model is developed which enabled concurrent delivery of substances of interest directly into the MBH and DVC but with no direct infusate contact between the two brain regions, and examination of neuronal communication between the MBH and the DVC in glucose regulation in vivo.

Pharmacological inhibition of DVC NMDA receptors abolishes hypothalamic lactate metabolism to lower glucose production. We inhibited DVC NMDA receptors via DVC delivery of MK-801 at a concentration that blocked DVC NMDA receptor agonist to lower glucose production (12). We infused DVC MK-801 and lactate into MBH (Fig. 1a,b). During the clamps, MBH lactate + DVC saline increased glucose infusion (Fig. 1d) and decreased glucose production (Fig. 1e,f) compared to MBH/DVC saline in the presence of similar plasma insulin levels (Table S1) and glucose uptake (Fig. 1g). In contrast, DVC MK-801 abolished the ability of MBH lactate to increase glucose infusion (Fig. 1d) and decrease glucose production (Fig. 1e,f) at the presence of similar plasma insulin levels (Table S1). These data suggest that DVC NMDA receptors mediate hypothalamic lactate metabolism to lower glucose production.

Pharmacological inhibition of DVC NMDA receptors abolishes hypothalamic AMPK inhibition to lower glucose production. To alternatively activate hypothalamic nutrient sensing and evaluate the necessity of DVC NMDA receptors, DVC MK-801 was infused to rats that had hypothalamic expression of the dominant negative form of AMPK via MBH injection of adenovirus expressing the dominant negative form of AMPK (Ad-DN AMPK α2 [D157A] (21)) during the clamps.
A hypothalamic-DVC axis that regulates glucose production (Fig. 2a,b). In the presence of similar plasma insulin levels (Table S2 in the online appendix), MBH DN-AMPK rats with DVC saline had higher glucose infusion (Fig. 2c) and lower glucose production (Fig. 2d,e) compared to MBH GFP rats with DVC saline. This is consistent with our recent findings indicating that MBH DN-AMPK lowers glucose production independent of changes in food intake and body weight (18), and strengthened the claim that DVC surgery itself did not affect glucose regulation. DVC MK-801 negated the increase in glucose infusion (Fig. 2c) and decrease in glucose production (Fig. 2d,e) in MBH DN-AMPK rats. Glucose uptake was comparable in all groups (Fig. 2f). Thus, DVC NMDA receptors are required for hypothalamic AMPK inhibition to lower glucose production.

**Molecular inhibition of DVC NMDA receptors abolishes hypothalamic AMPK inhibition to lower glucose production.** The NMDA receptor is composed of NR1 and NR2 subunits (22). We recently constructed an adenovirus expressing the shRNA of NR1 (Ad-shRNA NR1) and injected this Ad-shRNA NR1 into the DVC of rats to knock down DVC NR1 (12). Here, we injected the same Ad-shRNA NR1 into the DVC to inhibit DVC NMDA receptor-mediated neurotransmission and tested whether hypothalamic nutrient sensing activated by MBH Ad-DN AMPK is impaired (Fig. 3a,b). MBH DN AMPK / DVC Ad-mm rats required higher glucose infusion compared to MBH GFP / DVC mm rats to maintain euglycemia (Fig. 3c) due to an inhibition of glucose production (Fig. 3d,e), rather than changes in glucose uptake (Fig. 3f) and plasma insulin levels (Table S3 in the online appendix). MBH DN AMPK / DVC shRNA-NR1 rats did not have this elevated glucose infusion (Fig. 3c) or a drop in glucose production (Fig. 3d,e) compared to the corresponding control in the presence of similar plasma insulin levels (Table S3). These studies demonstrate that DVC NR1 subunit of the NMDA receptor is required for hypothalamic AMPK inhibition to lower glucose production.

**DVC NMDA receptor blockage disrupts glucose homeostasis during refeeding.** We addressed the physiological relevance of the ability of DVC NMDA receptor to integrate nutrient sensing to regulate glucose homeostasis using a fasting-refeeding non-clamp protocol. When fasted rodents are subjected to refeeding, the rise in plasma glucose levels is restrained due to an inhibition of gluconeogenesis (23). We reasoned that if the nutrient-sensing related signal(s) activated by refeeding are integrated at the DVC NMDA receptors to regulate glucose homeostasis (as suggested by the above hypothalamic as well as the recent gut (13;14) nutrient sensing studies), direct inhibition of DVC NMDA receptors during refeeding should disrupt glucose homeostasis. We first subjected our rats to a fast after one week of DVC surgery (Fig. 4a,b). Plasma glucose levels (Fig. 4b) and cumulative food intake (Fig. 4c) rose respectively after refeeding for the DVC saline rats. We next infused DVC MK-801 {at the same dose that negated the ability of hypothalamic lactate metabolism (Fig 1e) or DN AMPK (Fig. 2d) to lower glucose production} and upon refeeding, plasma glucose levels rose significantly higher than DVC saline rats (Fig. 4b) in the presence of similar cumulative food intake (Fig. 4c). Thus, our data indicates that DVC NMDA receptors integrate nutrient sensing to regulate glucose homeostasis.

**DISCUSSION**

We demonstrated that hypothalamic nutrient sensing triggers a forebrain-hindbrain NMDA dependent neuronal axis to lower glucose production. The cross-talk between the hypothalamus and the DVC in glucose regulation, however, remains to be clarified.
For example, it is crucial to assess whether the descending projection from the hypothalamus to the DVC is direct or indirect through other nuclei such as the paraventricular hypothalamus (PVN) since a recent study reports that hypothalamic leucine sensing activates DVC neurons via PVN oxytocin neurons to lower food intake (24). The necessity of a forebrain-hindbrain axis in glucose regulation by hypothalamic hormonal action also warrants future investigations since hepatic vagus is required for hypothalamic leptin to increase hepatic insulin sensitivity as well (2).

We implicated that DVC neurons expressing NMDA receptors are required specifically for the hypothalamic nutrient sensing to lower glucose production. Inhibition of DVC NMDA receptors, however, also negate lipid sensing in the intestine to lower glucose production (13;14) and food intake (9;10) while the activation of hypothalamic nutrient sensing is absence. These studies suggest that DVC NMDA receptor expressing neurons integrate signal(s) derived from nutrient sensing to regulate glucose and energy homeostasis but do not exclude the involvement of other neuronal systems since a recent study reports that serotonergic neurons in the brainstem mediates leptin action to regulate food intake (25). Lastly, in addition to the need in clarifying the neuronal systems in extra-hypothalamic regions that mediate hypothalamic nutrient sensing to lower glucose production, it is equally important to test for a glucose-regulatory role of nutrient sensing in MBH-nearby regions such as the dorsomedial (DMH) and lateral hypothalamic (LHA) area, such that advancement in this field is made in a better-defined context.

Author contributions. C.K.L.L. conducted and designed experiments, performed data analyses and wrote the manuscript; M.C., assisted in experiments. G.A.R. supplied the adenovirus expressing the dominant negative form of AMPK or GFP control. T.K.T.L. supervised the project, designed experiments and reviewed/edited the manuscript.

ACKNOWLEDGEMENTS
This work was supported by a research grant to T.K.T.L from the Canadian Institute of Health Research (MOP-86554). C.K.L.L. was supported by the Canadian Institute of Health Research graduate award. M.C. was supported by the Ontario Graduate Scholarship and a graduate studentship from the Banting and Best Diabetes Centre at the University of Toronto. G.A.R. is supported by a Programme Grant from the Wellcome Trust, by the Medical Research Council (UK) and by the European Union (FP7 “IMIDIA”). T.K.T.L. holds the John Kitson McIvor Endowed Chair in Diabetes Research and the Canada Research Chair in Obesity at the Toronto General Research Institute and University of Toronto.

FIGURE LEGENDS
Figure 1. DVC MK-801 abolished the glucose production-lowering effect induced by hypothalamic lactate infusion. (a) Schematic representation of working hypothesis: Infusion of NMDA antagonist MK-801 in the DVC negates the glucose production-lowering effect of MBH lactate. (b) Schematic representation of experimental design: MBH and DVC stereotaxic surgery were performed on male Sprague Dawley rats (~240-280g). After 1 week of recovery (day 7), vascular surgery (i.e. intravenous catheterization) was performed. Rats were given 5 recovery days until clamp studies (day 11), upon which DVC infusion of saline or MK-801 were given to MBH.
lactate-infusing animals. To verify the anatomical placement of cannulae and to confirm that infusion was localized, radioactive tracer administered in the MBH or DVC via the bilateral cannulae was found to be contained within the respective tracer-infused tissues (c). DVC administration of MK-801 in lactate-infused animals prevented the expected increase in glucose infusion rate (d) and lowering in glucose production (e) found to be elicited by MBH lactate. (f) Suppression of glucose production during the clamp period was expressed as percent decrease from basal glucose production. (g) Glucose utilization was comparable in all groups. MBH saline + DVC saline (n=5), MBH saline + DVC MK-801 (n=5), MBH lactate + DVC saline (n=5), MBH lactate + DVC MK-801 (n=6), *P < 0.01, + P < 0.001.

Figure 2. DVC MK-801 abolished the glucose production-lowering effect induced by hypothalamic expression of DN AMPK. (a) Schematic representation of working hypothesis: Infusion of NMDA antagonist MK-801 in the DVC negates the glucose production-lowering effect of MBH DN AMPK. (b) Schematic representation of experimental design: MBH and DVC stereotaxic surgery were performed on male Sprague Dawley rats (~240-280g). Virus-injected animals were administered 3µl of GFP- or DN AMPK-expressing adenovirus per side of cannulae immediately post-surgery. After 1 week of recovery (day 7), vascular surgery (i.e. intravenous catheterization) was performed. Rats were given 5 recovery days until clamp studies (day 11), upon which DVC infusion of saline or MK-801 were given to MBH virus-injected rodents. DVC administration of MK-801 in adenoviral-DN AMPK-injected rodents prevented the expected increase in glucose infusion rate (c) and lowering in glucose production (d) found to be elicited by DN AMPK. (e) Suppression of glucose production during the clamp period was expressed as percent decrease from basal glucose production. (f) Glucose utilization was comparable in all groups. MBH GFP + DVC saline (n=5), MBH GFP + DVC MK-801 (n=6), MBH DN AMPK + DVC saline (n=6), and MBH DN AMPK + DVC MK-801 (n=5). # P < 0.01, + P < 0.001.

Figure 3. Molecular knockdown of DVC NR1 negated the glucose production-lowering effect of hypothalamic expression of AMPK-DN. (a) Schematic representation of working hypothesis: Molecular knockdown of the NR1 subunit of the NMDA receptor in the DVC negates the glucose production-lowering effect of MBH DN AMPK. (b) Schematic representation of experimental design: MBH and DVC stereotaxic surgeries were performed on male Sprague Dawley rats (~240-280g). Animals were injected with 3ul/side of cannulae of adenovirus into the MBH (GFP or DN AMPK) and into the DVC (MM or shRNA-NR1) immediately post-surgery. After 1 week of recovery (day 7), vascular surgery (i.e. intravenous catheterization) was performed. Rats were given 5 recovery days until clamp studies (day 11). Animals with simultaneous disruption of both MBH AMPK and DVC NR1 did not exhibit the expected increase in glucose infusion rate (c) and lowering in glucose production (d) of DN AMPK animals. (e) Suppression of glucose production during the clamp period was expressed as percent decrease from basal glucose production. (f) Glucose utilization was comparable in all groups. MBH GFP+ DVC MM (n=5), MBH GFP + DVC NR1 (n=5), MBH DN AMPK + DVC MM (n=6) and MBH DN AMPK + DVC NR1 (n=5). # P < 0.01.

Figure 4. DVC MK-801 administration disrupts glucose homeostasis during refeeding. (a) Schematic representation of experimental design. DVC stereotaxic surgery was performed on male SD rats (~240-280g). After 1 week of recovery, animals were subjected to a 40-hour fast
A hypothalamic-DVC axis that regulates glucose production

(from 5 p.m. on day 7 until 9 a.m. on day 9). Thirty min before the completion of the 40-hour fast (i.e. time -30 min of refeeding protocol), rats were infused with DVC-saline or –MK-801. Rats were refed on regular chow ad libitum at time 0 min where food intake and blood glucose levels were monitored for 1 hr (time 15, 30, 45 & 60 min). At the fasting state (time -30 & 0 min), rats receiving DVC saline or MK-801 have comparable plasma glucose levels representative of fasting animals. During 1 hr of refeeding, DVC MK-801 infused rats have significantly higher plasma glucose levels compared to DVC-saline infused rats at 30, 45 and 60 min after refeeding. (c) Cumulative Food intake was comparable in both groups during 1 hr refeeding. DVC Saline (n=7), DVC MK-801 (n=6). * P < 0.001.

REFERENCES


A hypothalamic-DVC axis that regulates glucose production

Figure 1

A hypothalamic-DVC axis that regulates glucose production

D

Glucose Infusion Rate (mg/kg/min)

DVC Saline DVC MK801 DVC Saline DVC MK801

MBH Saline MBH Lactate

E

Glucose Production (mg/kg/min)

DVC Saline DVC MK801 DVC Saline DVC MK801

MBH Saline MBH Lactate

C

MBH ³H Administration

Radioactivity (cpm/mg tissue)

MBH DVC Cortex

DVC ³H Administration

Radioactivity (cpm/mg tissue)

MBH DVC Cortex
A hypothalamic-DVC axis that regulates glucose production

Figure 2

A hypothalamic-DVC axis that regulates glucose production

D

Glucose Production (mg/kg/min)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>MBH GFP</th>
<th>MBH DN-AMPK</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVC Saline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVC MK301</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

E

Glucose Suppression (%)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>MBH GFP</th>
<th>MBH DN-AMPK</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVC Saline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVC MK301</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

Glucose Infusion Rate (mg/kg/min)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>MBH GFP</th>
<th>MBH DN-AMPK</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVC Saline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVC MK301</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

F

Glucose Utilization (mg/kg/min)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>MBH GFP</th>
<th>MBH DN-AMPK</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVC Saline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DVC MK301</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
A hypothalamic-DVC axis that regulates glucose production

Figure 3

A hypothalamic-DVC axis that regulates glucose production

Figure 4

A hypothalamic-DVC axis that regulates glucose production